CAC 40 Down Nearly 2% As Stocks Fall On Tariff Woes

French equities are experiencing significant selling pressure, with the CAC 40 down nearly 2%, primarily driven by new U.S. tariffs on European exports and broader trade concerns. Pharma stocks are also notably impacted by U.S. drug pricing demands. Individual companies like Teleperformance and AXA are seeing sharp declines following lowered guidance and missed profit estimates, respectively, against a backdrop of a contracting French manufacturing PMI and stable Eurozone inflation at target.

Analysis

The French equity market is experiencing a significant, broad-based sell-off, with the benchmark CAC 40 declining 1.9% to 7,624.03. The primary catalyst is the announcement of new U.S. trade tariffs, including a 15% duty on European exports, which directly threatens the outlook for French multinational corporations. This macro pressure is compounded by negative company-specific news. Teleperformance's stock has plummeted over 16% after the company reduced its 2025 revenue growth guidance to the lower end of its 2% to 4% range. Similarly, insurer AXA is down 6.7% following a first-half profit miss. The pervasive negative sentiment is evident as even companies reporting growth, such as Saint-Gobain with a 3.4% sales increase, are seeing their stocks fall sharply. The domestic economic backdrop offers little relief, with the HCOB France Manufacturing PMI for July remaining in contractionary territory at 48.2. While headline Eurozone inflation is stable at the ECB's 2% target, core inflation remains elevated at 2.3%, potentially limiting policy support. In a starkly negative market, Orange and Danone are notable outliers, posting gains of over 2% and 1.75% respectively, suggesting unique company-specific strengths.

Key Decisions for Investors

• Given the new U.S. tariffs, investors should immediately review their portfolio's exposure to French exporters with significant U.S. revenue streams, as they are most vulnerable to margin compression and demand shocks.
• The severe punishment of companies like Teleperformance and AXA for negative guidance and earnings misses suggests the market is in a risk-off mode; it may be prudent to reduce positions in companies with high valuations or upcoming earnings reports that carry a high risk of disappointment.
• The contracting French manufacturing PMI signals underlying economic weakness, so investors should monitor leading economic indicators closely, while the resilience of stocks like Orange warrants investigation to identify potentially defensive assets in a volatile market.